122225-53-0

Usage

Uses

Used in Organic Chemistry:
Boc-(S)-2-amino-3-(imidazol-1-yl)propanoic acid is used as a building block for the synthesis of complex organic molecules, leveraging its imidazole group's reactivity and the chiral center's stereoselectivity.
Used in Peptide Synthesis:
In the pharmaceutical industry, Boc-(S)-2-amino-3-(imidazol-1-yl)propanoic acid is used as a protected amino acid for the stepwise assembly of peptides, taking advantage of the Boc group to prevent side reactions during the synthesis process.
Used in Medicinal Chemistry:
Boc-(S)-2-amino-3-(imidazol-1-yl)propanoic acid is utilized as a key intermediate in the development of new pharmaceuticals, where its unique structural features can be exploited to create novel bioactive compounds with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, Boc-(S)-2-amino-3-(imidazol-1-yl)propanoic acid is employed as a model compound to study the reactivity of imidazole groups and the influence of the Boc protecting group on the synthesis and properties of amino acids and their derivatives.

Upstream product

• 98541-64-1 (S)-3-(tert-butoxycarbonylamino)-oxetan-2-one 
• 18156-74-6 1-(Trimethylsilyl)imidazole 
• 288-32-4 1H-imidazole 

Downstream Products

• 136010-48-5 H-3-imidazol-1-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 136010-45-2 N-(tert-butoxycarbonyl)-3-imidazol-1-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 

Relevant academic research and scientific papers

MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS

The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids

Novel, potent small molecule motilin receptor antagonists are described. These peptidomimetic macrocycles are composed of a tripeptide cyclized backbone-to-backbone with a nonpeptidic tether and bear new unnatural amino acids containing basic side chains.

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides

A systematic evaluation of structure-absorption relationships using a high throughput intraduodenal rat screening model has led to the delineation of a set of structural parameters that appear to govern bioavailability in a series of peptide-based renin inhibitors. Optimum structures, exemplified by 25 and 41, incorporated a single, solubilizing substituent at the C- or N- terminus combined with a lipophilic P2-site residue. Both inhibitors gave unprecedented plasma drug levels upon intraduodenal administration to monkeys, and the calculated bioavailability for 41 (14 ± 4%) is the highest reported for any peptidic renin inhibitor.